Matinas BioPharma Holdings, Inc. Stockholders Equity

Quick Answer

Matinas BioPharma Holdings, Inc. reported Stockholders Equity of $4.83 million for fiscal year 2025.

Matinas BioPharma Holdings, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $4.83M -36.4%
2024 $7.59M -60.6%
2023 $19.25M -47.5%
2022 $36.64M -30.2%
2021 $52.49M -17.6%
2020 $63.73M +92.8%
2019 $33.05M +104.8%
2018 $16.14M +51.1%
2017 $10.68M +49.4%
2016 $7.15M +17.7%
2015 $6.07M +172.6%
2014 $2.23M -78.7%
2013 $10.47M +9084.1%
2012 -$116.6K

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $6.46M -59.1% -15.8%
June 30, 2025 $7.67M -59.8% +22.4%
March 31, 2025 $6.27M -56.9% -17.4%
December 31, 2024 $7.59M -60.6% -51.9%
September 30, 2024 $15.78M -31.8% -17.4%
June 30, 2024 $19.10M -31.4% +31.2%
March 31, 2024 $14.56M -55.4% -24.4%
December 31, 2023 $19.25M -47.5% -16.9%
  • Matinas BioPharma Holdings, Inc. showed a decrease of -36.4% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2012–2025 period, Matinas BioPharma Holdings, Inc.’s stockholders equity has grown by 4242.7% (from -$116.6 thousand to $4.83 million).
  • The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment